Literature DB >> 4049249

Hürthle cell tumor behavior: dilemma and resolution.

I B Rosen, S Luk, I Katz.   

Abstract

Thirty-four patients with the diagnosis of Hürthle cell tumor occurring from 1971 to 1984 were reviewed to help delineate an acceptable treatment policy. Twenty-nine of these occurred in the last 5 years of study so that extensive follow-up was not possible. Patients varied from age 17 years to 82 and consisted of five males and 29 females, most of whom had an asymptomatic solitary cold nodule. There was a 26% incidence of malignancy. One patient died of cancer caused by anaplastic change of underlying disease; this woman had refused surgery after an incisional biopsy specimen showed benign Hürthle cell tumor. Surgery consisting of lobectomy in 16 patients and near-total thyroidectomy in 18 was uncomplicated. No nodal surgery was necessary. Eighteen percent of patients had multicentric disease of which one half were malignant. Twelve percent of patients developed contralateral Hürthle cell tumor after lobectomy. Associated thyroid lesions occurred in 30% of patients, hyperparathyroidism in 10%. There are polar views in the literature on the management of these patients. While our own tumor experience has been reassuring, we feel that in view of the paucity of cases, those who view this tumor in a serious light deserve attention. Accordingly we advocate near-total thyroidectomy as a primary operation for those who are fit, lesser procedures for the disabled, and the difficult situation, and node sampling to detect early metastasis and improved survival in this group. It is apparent that further reporting of long-term follow-up experience is necessary for complete resolution of dilemmas in the treatment of this problem.

Entities:  

Mesh:

Year:  1985        PMID: 4049249

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

Review 1.  Benign Hürthle cell tumors of the thyroid: a diagnosis to be trusted?

Authors:  C S Grant; D Barr; J R Goellner; I D Hay
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

2.  Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid.

Authors:  J J Ryan; I D Hay; C S Grant; L M Rainwater; G M Farrow; J R Goellner
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

3.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

4.  Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment.

Authors:  Adolfo Pisanu; Luigi Sias; Alessandro Uccheddu
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

5.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

6.  The value of measurement of ras oncogenes and nuclear DNA analysis in the diagnosis of Hürthle cell tumors of the thyroid.

Authors:  C Schark; N Fulton; T Yashiro; G Stanislav; R Jacoby; F H Straus; H Dytch; M Bibbo; E L Kaplan
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

7.  Cell Cycle Regulatory Proteins p27(kip), Cyclins Dl and E and Proliferative Activity in Oncocytic (Hurthle Cell) Lesions of the Thyroid.

Authors:  Lincoln J. Maynes; Michael J. Hutzler; Nilima A. Patwardhan; Songtao Wang; Ashraf Khan
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

8.  Hürthle cell carcinoma: diagnostic and therapeutic implications.

Authors:  Mohamed R Hanief; Laszlo Igali; Dimitrie Grama
Journal:  World J Surg Oncol       Date:  2004-08-11       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.